Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Maja Lind-Hansen"'
Autor:
Joanna Vitfell-Rasmussen, Ian Judson, Akmal Safwat, Robin L. Jones, Philip Blach Rossen, Maja Lind-Hansen, Poul Knoblauch, Anders Krarup-Hansen
Publikováno v:
Sarcoma, Vol 2016 (2016)
Background. Belinostat is a novel histone deacetylase inhibitor. Primary Objectives. Maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of belinostat (Bel) in combination with doxorubicin (Dox) in solid tumours (phase I) and response ra
Externí odkaz:
https://doaj.org/article/bf901b03196d47cd83c4ec0cdd396221
Autor:
Robin L. Jones, Akmal Safwat, Poul Knoblauch, Maja Lind-Hansen, Ian Judson, Anders Krarup-Hansen, Philip Rossen, Joanna Vitfell-Rasmussen
Publikováno v:
Sarcoma, Vol 2016 (2016)
Vitfell-Rasmussen, J, Judson, I, Safwat, A A, Jones, R L, Rossen, P B, Lind-Hansen, M, Knoblauch, P & Krarup-Hansen, A 2016, ' A Phase I/II Clinical Trial of Belinostat (PXD101) in Combination with Doxorubicin in Patients with Soft Tissue Sarcomas ', Sarcoma, vol. 2016, 2090271 . https://doi.org/10.1155/2016/2090271
Vitfell-Rasmussen, J, Judson, I, Safwat, A, Jones, R L, Rossen, P B, Lind-Hansen, M, Knoblauch, P & Krarup-Hansen, A 2016, ' A Phase I/II Clinical Trial of Belinostat (PXD101) in Combination with Doxorubicin in Patients with Soft Tissue Sarcomas ', Sarcoma, vol. 2016, 2090271 . https://doi.org/10.1155/2016/2090271
Sarcoma
Vitfell-Rasmussen, J, Judson, I, Safwat, A A, Jones, R L, Rossen, P B, Lind-Hansen, M, Knoblauch, P & Krarup-Hansen, A 2016, ' A Phase I/II Clinical Trial of Belinostat (PXD101) in Combination with Doxorubicin in Patients with Soft Tissue Sarcomas ', Sarcoma, vol. 2016, 2090271 . https://doi.org/10.1155/2016/2090271
Vitfell-Rasmussen, J, Judson, I, Safwat, A, Jones, R L, Rossen, P B, Lind-Hansen, M, Knoblauch, P & Krarup-Hansen, A 2016, ' A Phase I/II Clinical Trial of Belinostat (PXD101) in Combination with Doxorubicin in Patients with Soft Tissue Sarcomas ', Sarcoma, vol. 2016, 2090271 . https://doi.org/10.1155/2016/2090271
Sarcoma
Background. Belinostat is a novel histone deacetylase inhibitor.Primary Objectives. Maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of belinostat (Bel) in combination with doxorubicin (Dox) in solid tumours (phase I) and response rat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fda814769a270e60e8777f8343376b6e
https://doaj.org/article/bf901b03196d47cd83c4ec0cdd396221
https://doaj.org/article/bf901b03196d47cd83c4ec0cdd396221
Autor:
Philip Rossen, Poul Knoblauch, Joanna Vitfell-Rasmussen, Ian Judson, Maja Lind-Hansen, Akmal Safwat, Anders Krarup-Hansen, Robin L. Jones
Publikováno v:
Journal of Clinical Oncology. 33:10516-10516
10516 Background: Belinostat is a novel histone deacetylase (HDAC) inhibitor. This study assessed the MTD and DLTs of the combination of belinostat and doxorubicin in solid tumours (phase I) and ef...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c593d7fa5a29df61a65c2363a8058c50
https://doi.org/10.1200/jco.2015.33.15_suppl.10516
https://doi.org/10.1200/jco.2015.33.15_suppl.10516